Roth Capital set a $12.00 target price on Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Thursday morning. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reissued a hold rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Wednesday, August 8th. BidaskClub raised shares of Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, August 31st. Zacks Investment Research raised shares of Syros Pharmaceuticals from a hold rating to a buy rating and set a $13.00 target price for the company in a research report on Friday, August 10th. Cann reissued a buy rating and set a $26.00 target price on shares of Syros Pharmaceuticals in a research report on Tuesday, August 7th. Finally, JMP Securities set a $33.00 price target on shares of Syros Pharmaceuticals and gave the stock a buy rating in a report on Thursday, November 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $19.00.

NASDAQ:SYRS opened at $8.16 on Thursday. Syros Pharmaceuticals has a 52 week low of $6.25 and a 52 week high of $15.88. The company has a market cap of $274.62 million, a P/E ratio of -3.83 and a beta of 0.78.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, November 1st. The company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.02). The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million. As a group, equities analysts forecast that Syros Pharmaceuticals will post -1.87 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in Syros Pharmaceuticals by 10.0% during the third quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock valued at $925,000 after buying an additional 7,062 shares during the period. MetLife Investment Advisors LLC grew its position in Syros Pharmaceuticals by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock valued at $242,000 after buying an additional 7,230 shares during the period. JPMorgan Chase & Co. grew its position in Syros Pharmaceuticals by 2.3% during the third quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock valued at $4,406,000 after buying an additional 8,286 shares during the period. The Manufacturers Life Insurance Company grew its position in Syros Pharmaceuticals by 299.9% during the first quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after buying an additional 9,691 shares during the period. Finally, Rhumbline Advisers grew its position in Syros Pharmaceuticals by 87.6% during the second quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after buying an additional 10,494 shares during the period. Institutional investors own 62.94% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.